High-Dose Chemotherapy with Autologous Bone Marrow Support in Advanced Malignant Melanoma
| Autor: | H. Koeppler, K. H. Pflueger, R. Seitz, Klaus Havemann |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Adult
Male Melphalan Cancer Research medicine.medical_specialty Skin Neoplasms Nausea medicine.medical_treatment Antineoplastic Combined Chemotherapy Protocols medicine Mucositis Humans Neoplasm Metastasis Melanoma Bone Marrow Transplantation Chemotherapy Carmustine Dose-Response Relationship Drug business.industry Hematology Middle Aged medicine.disease Combined Modality Therapy Surgery medicine.anatomical_structure Oncology Vomiting Female Bone marrow medicine.symptom business medicine.drug |
| Zdroj: | Oncology Research and Treatment. 12:277-279 |
| ISSN: | 2296-5262 2296-5270 |
| DOI: | 10.1159/000216662 |
| Popis: | Eight patients with advanced malignant melanoma were treated with high-dose melphalan (80-90 mg/m2) and BCNU (600-800 mg/m2). In all patients autologous bone marrow preservation was performed prior to therapy. Bone marrow was stored for 48 h in a refrigerator at 10 degrees C and reinfused 48 h post-therapy. Three patients had a complete response (CR), 1 a partial response and 4 patients no response. Two patients with CR died 4 and 5 months after therapy. One had an interstitial pneumonitis and 1 patient died from unknown cause. The third patient had a relapse 12 months after therapy. Major side effects were severe nausea/vomiting and a mild mucositis. Two patients suffered from BCNU-related encephalopathy. All patients had a full hematologic reconstitution after 6 weeks. High-dose chemotherapy with autologous bone marrow support achieves a high response rate. Long-term disease-free survival, however, was not seen with this approach. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|